Immunomodulation by durvalumab and pomalidomide in patients with relapsed/refractory multiple myeloma

This study sought to understand how the programmed death ligand 1 (PD-L1) inhibitor durvalumab and the immunomodulatory agent pomalidomide regulate immune cell activation and function in patients with relapsed/refractory (RR) multiple myeloma (MM). Immunologic changes in peripheral blood and bone ma...

Descripción completa

Detalles Bibliográficos
Autores principales: Young, Mary H., Pietz, Greg, Whalen, Elizabeth, Copeland, Wilbert, Thompson, Ethan, Fox, Brian A., Newhall, Kathryn J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8361181/
https://www.ncbi.nlm.nih.gov/pubmed/34385543
http://dx.doi.org/10.1038/s41598-021-95902-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8361181/
https://www.ncbi.nlm.nih.gov/pubmed/34385543
http://dx.doi.org/10.1038/s41598-021-95902-x

Ejemplares similares